Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey

Saibil, Samuel D.; Fitzgerald, Barbara; Freedman, Orit; Amir, Eitan; Napolskikh, Julie; Salvo, Nadia; Dranitsaris, George; Clemons, Mark

doi:10.3747/co.v17i4.562

Cited by 48 publications

(34 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Docetaxel may be administered on either a weekly or, more commonly, a tri-weekly (i.e., once per three weeks) schedule,78 but the tri-weekly schedule with co-administration of cyclophosphamide is the most common regimen for early-stage BC. Docetaxel may also be given in various other regimens 79–81…”

Section: Chemotherapeutic Agents Used Shortly After Bc Diagnosismentioning

confidence: 99%

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Eisner¹,

Luoh²

2011

Current Eye Research

View full text Add to dashboard Cite

This review concerns the effects on vision and the eye of medications prescribed at three phases of treatment for women with early-stage breast cancer (BC): (1) adjuvant cytotoxic chemotherapy, (2) adjuvant endocrine therapy, and (3) symptomatic relief. The most common side effects of cytotoxic chemotherapy are epiphora and ocular surface irritation, which can be caused by any of several different regimens. Most notably, the taxane docetaxel can lead to epiphora by inducing canalicular stenosis. The selective-estrogen-receptor-modulator (SERM) tamoxifen, long the gold-standard adjuvant-endocrine-therapy for women with hormone-receptor-positive BC, increases the risk of posterior subcapsular cataract. Tamoxifen also affects the optic nerve head more often than previously thought, apparently by causing subclinical swelling within the first 2 years of use for women older than ∼50 years. Tamoxifen retinopathy is rare, but it can cause foveal cystoid spaces that are revealed with spectral-domain optical coherence tomography (OCT) and that may increase the risk for macular holes. Tamoxifen often alters the perceived color of flashed lights detected via short-wavelength-sensitive (SWS) cone response isolated psychophysically; these altered perceptions may reflect a neural-response sluggishness that becomes evident at ∼2 years of use. The aromatase inhibitor (AI) anastrozole affects perception similarly, but in an age-dependent manner suggesting that the change of estrogen activity towards lower levels is more important than the low estrogen activity itself. Based on analysis of OCT retinal thickness data, it is likely that anastrozole increases the tractional force between the vitreous and retina. Consequently, AI users, myopic AI users particularly, might be at increased risk for traction-related vision loss. Because bisphosphonates are sometimes prescribed to redress AI-induced bone loss, clinicians should be aware of their potential to cause scleritis and uveitis occasionally. We conclude by suggesting some avenues for future research into the visual and ocular effects of AIs, particularly as relates to assessment of cognitive function.

show abstract

Section: Chemotherapeutic Agents Used Shortly After Bc Diagnosismentioning

confidence: 99%

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Eisner¹,

Luoh²

2011

Current Eye Research

View full text Add to dashboard Cite

show abstract

“…5 Despite the widespread use of paclitaxel and the high frequency of P-APS, little is known about the natural history of this pain syndrome.…”

Section: Introductionmentioning

confidence: 99%

Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy

Reeves

Dakhil²,

Sloan

et al. 2012

Cancer

141

109

View full text Add to dashboard Cite

Background Paclitaxel causes an acute pain syndrome (P-APS), occurring within days after each dose and usually abating within days. Paclitaxel also causes a more classic peripheral neuropathy, which steadily increases in severity with increasing paclitaxel total doses. Little detail is available regarding the natural history of these two syndromes, or any relationship between them, although a recent publication does provide natural history data about weekly paclitaxel, supporting an association between the severity of P-APS and eventual peripheral neuropathy symptoms. Methods Patients entering this study were about to receive paclitaxel and carboplatin every 3 weeks. Daily questionnaires were completed for the first week after every chemotherapy dose and EORTC QLQ-CIPN 20 instruments were completed weekly. Results The P-APS severity peaked on day 4 after the initial chemotherapy dose, with 12%, 29%, 23%, and 36% of patients having maximal pain scores of 0, 1–4, 5–6, or 7–10 during the first week after the first dose of therapy, respectively. Patients with P-APS scores of 0–4 with the first dose of chemotherapy had less eventual sensory neuropathy than did patients with P-APS scores of 5–10 (p=0.001). With regard to the more peripheral neuropathy, sensory neuropathy was more problematic than was either motor or autonomic neuropathy. Numbness and tingling were more common components of the sensory neuropathy, than was pain. Conclusions Patients with worse P-APS severities appear to have more eventual chemotherapy induced peripheral neuropathy. This provides support for the concept that the P-APS is a form of nerve pathology.

show abstract

“…Patients, however, still experience fatigue, phlebitis, alopecia, nausea, mucositis, anemia, and myelosuppression alongside long-term side effects including ovarian failure, weight gain, cardiac dysfunction, and, in some cases, leukemia [64, 65]. Herbal medicines and natural supplements are widely used in cancer chemoprevention in the clinic and are also studied in vitro and in vivo [66, 67]. …”

Section: Resultsmentioning

confidence: 99%

Herbal Medicine and Acupuncture for Breast Cancer Palliative Care and Adjuvant Therapy

Liao

Apaya

Shyur

2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Breast cancer is a life-threatening disease among women worldwide with annual rates of reported incidence and death increasing alarmingly. Chemotherapy is a recommended and effective treatment option for breast cancer; however, the narrow therapeutic indices and varied side effects of currently approved drugs present major hurdles in increasing its effectiveness. An increasing number of literature evidence indicate that complementary and alternative medicine (CAM) used in treatment-related symptom control and alleviation of side effects plays an important role in increasing survival rate and quality of life in breast cancer patients. This review focuses on the use of herbal medicines and acupuncture in palliative care and as adjuvants in the treatment of breast cancer. Herbal medicinal treatments, the correlation of clinical use with demonstrated in vitro and in vivo mechanisms of action, and the use of certain acupoints in acupuncture are summarized. The aim of this review is to facilitate an understanding of the current practice and usefulness of herbal medicine and acupuncture as adjuvants in breast cancer therapy.

show abstract

Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey

Cited by 48 publications

References 12 publications

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy

Herbal Medicine and Acupuncture for Breast Cancer Palliative Care and Adjuvant Therapy

Contact Info

Product

Resources

About